Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination

We describe a case of second primary malignancy in a 65-year-old patient affected by polycythemia vera treated with the JAK 1/2 inhibitor ruxolitinib. The latter is recognized as a risk factor for the onset of non-melanoma skin cancers in many retrospective and perspective studies, but the concomita...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Chiara Masucci, Mauro Passucci, Emilia Scalzulli, Ida Carmosino, Marcello Capriata, Alessandro Costa, Claudia Ielo, Maurizio Martelli, Massimo Breccia
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Frontiers Media S.A. 2023-06-01
סדרה:	Frontiers in Oncology
נושאים:	avelumab Merkel cell carcinoma ruxolitinib polycytemia vera second malignancies
גישה מקוונת:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1212638/full
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!